LENZ Therapeutics, Inc. (LENZ:NASDAQ) closed at $3.16 on October 23, 2026, down 2.77% on the day. The stock trades 90.4% below its 52-week high of $32.92 and 3.1% above its 52-week low of $3.07. Over the past year, it lost 90.1%. LENZ Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, LENZ closed higher on 106 days (42%). Its best day was November 11, 2025 (+14.06%) and its worst was December 12, 2025 (-25.96%). The stock moved 10% or more in a single session 11 times. It opened at least 5% above the previous day's high 1 time.
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Find more stocks like LENZ with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.